Scotia looks to leverage its big deal

OXFORD - Britain's biotech sector has been given a welcome if modest boost with the news that Scotia Holdings (LSE:SOH) has signed licensing deals worth potentially in excess of $100 million.

SOH (Stirling, U.K.) signed licensing agreements with Boehringer Ingelheim and Kyowa Hakko Kogyo for the development

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE